Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31566582 | 0.91 | USP2 (0.41) | USP2SMN1; SMN2EPHX2HPGDOPRD1 | |
| SCHEMBL17447773 | 0.88 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1NAMPT | |
| SCHEMBL16123523 | 0.88 | USP2 (0.46) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL19156954 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2EPHX2EPHX1NAMPT | |
| SCHEMBL2943334 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL6896206 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL5523316 | 0.85 | USP2 (0.44) | USP2SMN1; SMN2EPHX2EPHX1NAMPT | |
| SCHEMBL26233896 | 0.84 | USP2 (0.41) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL15742968 | 0.83 | USP2 (0.45) | USP2SMN1; SMN2EPHX2EPHX1HPGD | |
| SCHEMBL18418212 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2EPHX2EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4339192-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Regents of the University of California (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3478284-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3515916-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-18 | — | — | US | disclosed |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-24 | — | — | US | disclosed |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-4056562-A1 | HETEROCYCLIC INHIBITORS OF BRUTON'S TYROSINE KINASE | Merck Patent GmbH (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-109661229-B | Compounds and compositions for the treatment of cancer | 加利福尼亚大学董事会 | 2022-06-28 | — | — | CN | disclosed |
| EP-2718270-B1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-9580449-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9073947-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20070185106-A1 | Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150942-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, HCCS, CFTR | USP2 3690/4885SMN1; SMN2 3421/4885EPHX2 2802/4885 |
| US-11560356-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | USP2 3690/4885SMN1; SMN2 3421/4885EPHX2 2802/4885 |
| US-20070185106-A1 | Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists | GNRHR, PRLHR, GHRHR | USP2 3195/4885SMN1; SMN2 4631/4885EPHX2 3548/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | USP2 3501/4885SMN1; SMN2 4722/4885EPHX2 1690/4885 |
| US-11529347-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPN21, PTPN22, PTPN5 | USP2 1866/4885SMN1; SMN2 430/4885EPHX2 2331/4885 |
| US-12227482-B2 | Compounds and compositions for the treatment of cancer | TP53, HCCS, CFTR | USP2 3690/4885SMN1; SMN2 3421/4885EPHX2 2802/4885 |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | NOS1, NOS2, ASS1 | USP2 4129/4885SMN1; SMN2 35/4885EPHX2 1230/4885 |
| US-20150259363-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | USP2 3501/4885SMN1; SMN2 4722/4885EPHX2 1690/4885 |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | USP2 3501/4885SMN1; SMN2 4722/4885EPHX2 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.